Broader Tinlarebant Trials

In parallel, Belite has completed enrollment in a Phase 2/3 study of tinlarebant in adolescent STGD1 patients (DRAGON II) and launched a Phase 3 PHOENIX trial to evaluate efficacy in geographic atrophy associated with age‑related macular degeneration. These parallel trials aim to broaden tinlarebant’s therapeutic reach beyond STGD1.